



Investor Presentation February 2007

Bill Mobbs
CEO
ITL Limited

ITL Limited

ITL (ASX: ITD, www.itl-limited.com) is a rapidly emerging multinational in the healthcare industry. ITL specialises in creating innovative medical devices and procedure packs for global healthcare markets. ITL manufactures in Australia and Malaysia, and has representative offices in North America, Europe and Asia.

ITL patented products have a presence in over 35 countries and protect the lives and health of healthcare workers in millions of procedures annually.

ITL supplies its range of customized procedure packs to over 200 public and private hospitals across Australia as well as capital equipment, instruments and procedure packs to over 160 private and public hospitals and agents in Malaysia.




2006 Results



	First half 2007		First half 2006
Revenue	\$20.3M	↑ 52%	\$13.1M
Profit before tax	\$ 2.1M	↑ 60%	\$ 1.3M
Profit after tax	\$ 1.9M	↑ 109%	\$ 0.9M
EBITDA	\$ 2.9M	↑ 61%	\$ 1.8M

Revenue Performance

	2003	2004	2005	2006	2007
Revenue	\$8.8M	\$17.6M	\$24.2M	\$31.3M	\$38.0M



Six Months in Review

- Maiden dividend
- New facility in Melbourne
- Land purchase in Malaysia
 - On target for new factory in Malaysia next 12 months
- US Platypus litigation finalised
- Surgicare litigation finalised



Looking Forward

- New sterilisation capacity
- New business system
- New factory in Malaysia
- Acquisitions



Region 1

Australia / New Zealand

- Contract sterilisation issues
- Repositioning this business for the future
 - Relocated the manufacturing facility
 - Next scale of manufacturing capacity
 - Vertical integration
 - Steriliser online 2nd half



Region 2 – SE Asia

- Strong Revenue Result
 - Capital Equipment 70%
 - Consumables 30%
- Smooth integration
- Positive Acquisition
 - Solid delivery to shareholders
- Actively pursuing acquisitions




Region 3 – Rest of the World


- Sales up 25%
- Mainly patent protected products
- Re-signed Héma-Québec
- New contract with bioMérieux
- Strong product pipeline



Product Pipeline

- 9% of Revenue
 - 50% underpinned by grants
- Some examples
 - TINA
 - Trials with Fresenius
 - Wholeblood (blood donation)
 - Dialysis (kidney)
 - Croc Clamp





Innovating Technologies for Life